Index RUT P/E - EPS (ttm) -3.54 Insider Own 31.21% Shs Outstand 41.21M Perf Week 5.96%
Market Cap 865.22M Forward P/E - EPS next Y -4.66 Insider Trans 2.10% Shs Float 31.58M Perf Month 36.20%
Income -147.71M PEG - EPS next Q -1.13 Inst Own 74.39% Short Float 12.92% Perf Quarter 4.78%
Sales 0.00M P/S - EPS this Y 74.20% Inst Trans - Short Ratio 15.96 Perf Half Y -41.51%
Book/sh 9.51 P/B 1.98 EPS next Y -9.25% ROA - Short Interest 4.08M Perf Year -
Cash/sh 9.66 P/C 1.95 EPS next 5Y - ROE - 52W Range 13.14 - 33.92 Perf YTD -18.57%
Dividend Est. - P/FCF - EPS past 5Y - ROI -31.86% 52W High -44.43% Beta -
Dividend TTM - Quick Ratio 16.96 Sales past 5Y 0.00% Gross Margin - 52W Low 43.46% ATR (14) 1.15
Dividend Ex-Date - Current Ratio 16.96 EPS Y/Y TTM - Oper. Margin 0.00% RSI (14) 60.45 Volatility 6.97% 6.76%
Employees - Debt/Eq 0.06 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 31.50
Option/Short No / Yes LT Debt/Eq 0.06 EPS Q/Q -187.82% Payout - Rel Volume 0.77 Prev Close 19.21
Sales Surprise - EPS Surprise -1.56% Sales Q/Q - Earnings Aug 12 AMC Avg Volume 255.62K Price 18.85
SMA20 11.80% SMA50 13.44% SMA200 -4.22% Trades
Volume 196,293 Change -1.87%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-22-24 Initiated H.C. Wainwright
Buy
$33
Jul-08-24 Initiated Chardan Capital Markets
Buy
$28
Jun-27-24 Initiated Piper Sandler
Overweight
$37
Dec-05-23 Initiated Truist
Buy
$34
Dec-05-23 Initiated TD Cowen
Outperform
Dec-05-23 Initiated JP Morgan
Overweight
$23
Dec-05-23 Initiated Jefferies
Buy
$28
Aug-16-24 08:53PM
06:50PM
Aug-12-24 04:05PM
Jul-10-24 08:00AM
Jun-04-24 04:05PM
01:56PM
Loading…
01:56PM
May-30-24 06:00AM
May-28-24 08:05AM
08:00AM
May-22-24 12:00PM
09:55AM
May-14-24 09:54PM
04:05PM
Apr-15-24 04:05PM
Mar-21-24 10:53PM
04:05PM
Loading…
04:05PM
Feb-29-24 04:01PM
Jan-03-24 08:05AM
Dec-18-23 04:04PM
(Commercial Observer)
+13.88%
Dec-13-23 10:51PM
04:05PM
Dec-11-23 07:53PM
Cargo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of cell therapies for cancer patients. It is involved in evaluating its lead program, CRG-022, an autologous CD22 chimeric antigen receptor T-cell therapy candidate, in a potentially pivotal Phase 2 clinical trial in patients with large B-cell lymphoma whose disease relapsed or was refractory to CD19 CAR T-cell therapy. The company was founded by Crystal Mackall, Nancy Goodman, Louai Labanieh, and Robbie Majzner in December 2019 and is headquartered in San Carlos, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Samsara BioCapital GP, LLC 10% Owner May 30 '24 Buy 17.00 294,000 4,998,000 4,415,689 Jun 03 09:45 PM Samsara BioCapital GP, LLC 10% Owner Nov 14 '23 Buy 15.00 666,666 9,999,990 4,121,689 Nov 16 07:39 PM Third Rock Ventures V, L.P. 10% Owner Nov 14 '23 Buy 15.00 1,333,333 19,999,995 1,807,119 Nov 14 07:08 PM PERCEPTIVE ADVISORS LLC Former 10% Owner Nov 14 '23 Buy 15.00 666,666 9,999,990 2,912,835 Nov 14 04:32 PM
Index RUT P/E - EPS (ttm) -2.69 Insider Own 54.90% Shs Outstand 41.13M Perf Week -10.66%
Market Cap 558.47M Forward P/E - EPS next Y -3.36 Insider Trans -2.83% Shs Float 22.43M Perf Month -0.44%
Income -119.67M PEG - EPS next Q -0.86 Inst Own 45.80% Short Float 6.47% Perf Quarter -16.51%
Sales 0.00M P/S - EPS this Y -65.66% Inst Trans - Short Ratio 6.16 Perf Half Y -19.67%
Book/sh 5.84 P/B 1.92 EPS next Y -1.98% ROA -39.26% Short Interest 1.45M Perf Year -7.34%
Cash/sh 6.26 P/C 1.80 EPS next 5Y - ROE -41.62% 52W Range 5.85 - 16.91 Perf YTD 30.58%
Dividend Est. - P/FCF - EPS past 5Y - ROI -41.25% 52W High -33.57% Beta 1.84
Dividend TTM - Quick Ratio 11.20 Sales past 5Y 0.00% Gross Margin - 52W Low 91.97% ATR (14) 0.70
Dividend Ex-Date - Current Ratio 11.20 EPS Y/Y TTM - Oper. Margin 0.00% RSI (14) 44.62 Volatility 5.83% 6.95%
Employees 28 Debt/Eq 0.00 Sales Y/Y TTM - Profit Margin - Recom 1.00 Target Price 32.50
Option/Short Yes / Yes LT Debt/Eq 0.00 EPS Q/Q -179.61% Payout - Rel Volume 0.43 Prev Close 11.94
Sales Surprise - EPS Surprise -18.57% Sales Q/Q - Earnings Aug 13 AMC Avg Volume 235.62K Price 11.23
SMA20 -0.74% SMA50 -7.78% SMA200 -3.68% Trades
Volume 101,807 Change -5.95%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-10-24 Initiated H.C. Wainwright
Buy
$30
Apr-02-24 Initiated Goldman
Buy
$30
Mar-07-23 Initiated Wells Fargo
Overweight
$27
Mar-07-23 Initiated Stifel
Buy
$45
Mar-07-23 Initiated Guggenheim
Buy
$32
Mar-07-23 Initiated Evercore ISI
Outperform
Mar-07-23 Initiated Credit Suisse
Outperform
$40
Mar-07-23 Initiated BofA Securities
Buy
$39
Aug-28-24 08:00AM
Aug-13-24 04:05PM
Aug-05-24 04:05PM
Jul-12-24 07:01PM
07:01PM
03:11AM
Loading…
Jun-21-24 03:11AM
Jun-15-24 02:53AM
Jun-14-24 08:00AM
02:43AM
Jun-03-24 08:00AM
May-13-24 11:45AM
May-09-24 11:56AM
07:00AM
May-06-24 08:00AM
May-02-24 08:00AM
12:16AM
Loading…
Apr-05-24 12:16AM
Mar-22-24 10:51AM
Mar-21-24 11:53AM
09:11AM
07:00AM
Mar-13-24 04:05PM
Feb-08-24 08:00AM
Jan-29-24 04:05PM
Jan-17-24 12:00PM
Jan-04-24 04:05PM
Dec-21-23 04:05PM
Nov-12-23 09:22AM
Nov-11-23 11:30AM
Nov-09-23 04:05PM
(GlobeNewswire) -9.31%
-12.84%
Nov-07-23 05:12PM
(GuruFocus.com) +8.02%
-6.74%
04:05PM
Loading…
04:05PM
Nov-02-23 10:00AM
Oct-31-23 04:05PM
Oct-13-23 04:10PM
(GlobeNewswire) +5.59%
+5.19%
Sep-19-23 04:00PM
Sep-14-23 04:05PM
Sep-11-23 04:05PM
Sep-10-23 07:47AM
07:45AM
Sep-09-23 05:00AM
Sep-05-23 04:05PM
09:55AM
Aug-29-23 04:05PM
Aug-22-23 05:45PM
Aug-07-23 04:05PM
(GlobeNewswire) -6.02%
+6.96%
Jul-31-23 04:05PM
Jul-17-23 04:01PM
Jun-09-23 08:04AM
May-31-23 08:00AM
May-15-23 04:01PM
May-10-23 08:39AM
May-02-23 08:00AM
May-01-23 08:00AM
Apr-27-23 04:47PM
Mar-15-23 04:01PM
Mar-04-23 04:30PM
Mar-01-23 04:05PM
Feb-20-23 08:00AM
Feb-17-23 12:08PM
(American City Business Journals)
Feb-14-23 04:01PM
Feb-10-23 05:16PM
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Rodman David Malcom Chief Medical Officer Aug 12 '24 Option Exercise 0.84 11,365 9,565 114,238 Aug 13 04:20 PM Slingsby Brian Taylor Director Jul 24 '24 Sale 13.05 550,000 7,177,500 8,644,579 Jul 26 09:45 PM Rodman David Malcom Chief Medical Officer Jul 16 '24 Option Exercise 1.08 525 567 103,398 Jul 18 06:34 PM Rodman David Malcom Chief Medical Officer Jul 16 '24 Sale 15.00 525 7,876 102,873 Jul 18 06:34 PM Rodman David Malcom Chief Medical Officer Jul 12 '24 Option Exercise 1.08 6,349 6,857 102,873 Jul 12 04:39 PM Rodman David Malcom Chief Medical Officer Jul 11 '24 Option Exercise 0.54 5,017 2,709 96,524 Jul 12 04:39 PM Levy Adam Scott CFO and Secretary Jul 11 '24 Sale 13.14 10,757 141,394 247,611 Jul 12 04:37 PM Congleton Jon Chief Executive Officer Jul 11 '24 Sale 13.34 15,746 210,075 911,212 Jul 12 04:36 PM Congleton Jon Chief Executive Officer Jun 17 '24 Sale 12.25 17,766 217,712 958,505 Jun 20 05:44 PM Congleton Jon Chief Executive Officer Jun 18 '24 Sale 11.99 16,607 199,073 941,898 Jun 20 05:44 PM Congleton Jon Chief Executive Officer Jun 20 '24 Sale 11.73 14,940 175,237 926,958 Jun 20 05:44 PM Congleton Jon Chief Executive Officer Jun 13 '24 Sale 12.74 39,961 509,027 992,500 Jun 14 06:15 PM Congleton Jon Chief Executive Officer Jun 12 '24 Sale 12.77 16,607 212,013 1,032,461 Jun 14 06:15 PM Congleton Jon Chief Executive Officer Jun 14 '24 Sale 12.52 16,229 203,163 976,271 Jun 14 06:15 PM Levy Adam Scott CFO and Secretary Jun 11 '24 Sale 12.94 96,815 1,252,718 255,462 Jun 13 05:33 PM Rodman David Malcom Chief Medical Officer Jun 12 '24 Option Exercise 1.08 6,349 6,857 89,729 Jun 13 05:32 PM Rodman David Malcom Chief Medical Officer Jun 11 '24 Option Exercise 0.54 5,017 2,709 83,380 Jun 13 05:32 PM Rodman David Malcom Chief Medical Officer May 13 '24 Option Exercise 0.84 11,366 9,566 78,363 May 15 04:43 PM Rodman David Malcom Chief Medical Officer May 09 '24 Option Exercise 1.08 100 108 67,097 May 10 04:17 PM Rodman David Malcom Chief Medical Officer May 09 '24 Sale 15.00 100 1,500 66,997 May 10 04:17 PM Rodman David Malcom Chief Medical Officer Apr 12 '24 Option Exercise 1.08 6,349 6,857 66,997 Apr 15 04:24 PM Rodman David Malcom Chief Medical Officer Apr 11 '24 Option Exercise 0.54 5,017 2,709 60,648 Apr 15 04:24 PM Rodman David Malcom Chief Medical Officer Mar 12 '24 Option Exercise 1.08 6,348 6,856 55,631 Mar 13 05:35 PM Rodman David Malcom Chief Medical Officer Mar 11 '24 Option Exercise 0.54 5,017 2,709 49,283 Mar 13 05:35 PM Samsara BioCapital GP, LLC 10% Owner Feb 12 '24 Buy 13.50 555,555 7,499,992 5,074,916 Feb 14 09:06 PM Rodman David Malcom Chief Medical Officer Feb 12 '24 Option Exercise 0.84 11,366 9,566 44,266 Feb 13 04:08 PM Rodman David Malcom Chief Medical Officer Jan 12 '24 Option Exercise 1.08 6,348 6,856 32,900 Jan 12 04:01 PM Rodman David Malcom Chief Medical Officer Jan 11 '24 Option Exercise 0.54 5,017 2,709 26,552 Jan 12 04:01 PM Rodman David Malcom Chief Medical Officer Dec 11 '23 Option Exercise 0.54 5,018 2,710 20,069 Dec 12 05:08 PM Congleton Jon Chief Executive Officer Nov 22 '23 Buy 5.97 4,250 25,356 1,049,068 Nov 27 04:01 PM Rodman David Malcom Chief Medical Officer Nov 13 '23 Option Exercise 0.54 5,017 2,709 15,051 Nov 14 06:18 PM Rodman David Malcom Chief Medical Officer Nov 03 '23 Option Exercise 0.54 10,034 5,418 10,034 Nov 07 05:15 PM
Index RUT P/E - EPS (ttm) -2.33 Insider Own 18.37% Shs Outstand 75.98M Perf Week -13.84%
Market Cap 642.64M Forward P/E - EPS next Y -1.98 Insider Trans -0.15% Shs Float 65.33M Perf Month -2.67%
Income -203.85M PEG - EPS next Q -0.58 Inst Own 95.22% Short Float 22.83% Perf Quarter -14.85%
Sales 0.00M P/S - EPS this Y -13.00% Inst Trans -2.45% Short Ratio 18.30 Perf Half Y -49.88%
Book/sh 1.67 P/B 4.81 EPS next Y 11.78% ROA -79.66% Short Interest 14.91M Perf Year 28.89%
Cash/sh 2.38 P/C 3.37 EPS next 5Y - ROE -121.29% 52W Range 5.94 - 21.17 Perf YTD -57.29%
Dividend Est. - P/FCF - EPS past 5Y 8.79% ROI -105.14% 52W High -62.07% Beta 0.85
Dividend TTM - Quick Ratio 6.04 Sales past 5Y -5.25% Gross Margin - 52W Low 35.19% ATR (14) 0.61
Dividend Ex-Date - Current Ratio 6.04 EPS Y/Y TTM -2.48% Oper. Margin 0.00% RSI (14) 34.72 Volatility 7.29% 7.01%
Employees 150 Debt/Eq 0.51 Sales Y/Y TTM -100.00% Profit Margin - Recom 1.00 Target Price 27.86
Option/Short Yes / Yes LT Debt/Eq 0.45 EPS Q/Q -27.65% Payout - Rel Volume 0.72 Prev Close 8.59
Sales Surprise - EPS Surprise -1.63% Sales Q/Q - Earnings Aug 08 BMO Avg Volume 814.89K Price 8.03
SMA20 -12.03% SMA50 -9.10% SMA200 -38.53% Trades
Volume 586,385 Change -6.52%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-28-24 Initiated Raymond James
Strong Buy
$30
Oct-25-23 Upgrade Jefferies
Hold → Buy
$20
Apr-03-23 Resumed Piper Sandler
Overweight
$26
Sep-19-22 Resumed H.C. Wainwright
Buy
$30
Jul-12-22 Initiated Truist
Buy
$20
Mar-23-22 Initiated H.C. Wainwright
Buy
$24
Dec-22-21 Downgrade Jefferies
Buy → Hold
$52 → $28
Nov-19-21 Initiated Piper Sandler
Overweight
$56
Apr-26-21 Resumed Credit Suisse
Outperform
$65
Jan-11-21 Initiated Credit Suisse
Outperform
$65
Jan-06-21 Initiated JP Morgan
Overweight
$59
Mar-12-20 Initiated Robert W. Baird
Outperform
$35
Show Previous Ratings
Sep-05-24 12:02AM
Sep-04-24 08:00AM
Sep-02-24 05:22PM
Aug-29-24 08:00AM
Aug-16-24 04:15PM
04:32AM
Loading…
Aug-15-24 04:32AM
Aug-09-24 05:05AM
(Thomson Reuters StreetEvents)
Aug-08-24 07:00AM
Jul-23-24 08:00AM
Jul-12-24 04:15PM
Jul-08-24 06:42PM
12:30PM
Jun-24-24 07:00AM
Jun-18-24 04:15PM
Jun-03-24 04:00PM
08:00AM
Loading…
May-28-24 08:00AM
May-22-24 07:00AM
May-20-24 08:00AM
May-17-24 04:15PM
May-14-24 08:00AM
May-07-24 01:53PM
10:19AM
08:52AM
07:00AM
Apr-24-24 06:33AM
Apr-12-24 04:15PM
Mar-20-24 05:31AM
Mar-19-24 10:52PM
07:00AM
Mar-15-24 04:15PM
08:18AM
Loading…
08:18AM
Feb-28-24 08:00AM
Feb-16-24 04:15PM
Feb-15-24 08:00AM
Feb-06-24 08:00AM
Jan-25-24 08:00AM
Jan-23-24 08:00AM
Jan-22-24 07:00AM
(The Wall Street Journal)
Jan-18-24 05:01PM
Jan-12-24 04:15PM
Jan-04-24 08:00AM
Jan-02-24 01:57PM
Dec-30-23 07:01PM
Dec-19-23 08:00AM
Dec-15-23 04:15PM
Dec-10-23 09:05AM
Nov-17-23 04:15PM
Nov-12-23 12:32PM
Nov-07-23 08:14AM
07:15AM
Nov-06-23 09:55AM
Nov-03-23 11:52PM
04:00PM
Nov-02-23 08:00AM
Oct-31-23 08:50AM
Oct-24-23 12:00PM
Oct-23-23 08:00AM
Oct-19-23 09:55AM
08:00AM
Oct-18-23 08:30AM
Oct-16-23 04:15PM
(Business Wire) +5.36%
+5.33%
Oct-13-23 12:45PM
Oct-12-23 04:17PM
Oct-11-23 08:57PM
05:05PM
04:44PM
Sep-19-23 08:00AM
Sep-15-23 04:15PM
Sep-07-23 09:55AM
Aug-18-23 04:15PM
Aug-09-23 04:15PM
Aug-02-23 10:41AM
Jul-13-23 08:00AM
Jun-30-23 11:00AM
Jun-15-23 08:00AM
Jun-01-23 04:05PM
May-10-23 08:00AM
May-09-23 07:30AM
May-08-23 08:00AM
Apr-17-23 12:57PM
Apr-12-23 08:00AM
Apr-10-23 04:05PM
Mar-15-23 08:00AM
Mar-07-23 07:00AM
Mar-01-23 08:00AM
Feb-27-23 08:00AM
Feb-17-23 08:00AM
Feb-11-23 07:23AM
Feb-06-23 08:00AM
Jan-09-23 08:00AM
Jan-03-23 08:00AM
Nov-16-22 06:04AM
Nov-15-22 08:00AM
Nov-14-22 08:00AM
Nov-10-22 09:00AM
Nov-09-22 08:00AM
Nov-08-22 08:00AM
Oct-22-22 07:00AM
Oct-06-22 08:00AM
Oct-04-22 08:00AM
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the business of discovering, developing, and delivering innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company was founded by Timothy A. Springer and Leonard I. Zon in October 2012 and is headquartered in Cambridge, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Parlavecchio Caryn CHRO Aug 16 '24 Sale 9.33 1,451 13,538 151,988 Aug 19 05:00 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Jun 17 '24 Sale 8.98 2,315 20,800 144,704 Jun 18 05:56 PM Parlavecchio Caryn CHRO Jun 17 '24 Sale 8.98 4,305 38,680 153,439 Jun 18 05:55 PM Myles Edward H COO & CFO Jun 17 '24 Sale 8.98 9,458 84,978 201,518 Jun 18 05:54 PM Ho Junlin GENERAL COUNSEL Jun 17 '24 Sale 8.98 4,695 42,183 204,076 Jun 18 05:53 PM Myles Edward H COO & CFO Feb 16 '24 Sale 15.74 4,744 74,686 210,976 Feb 21 06:13 PM Qatanani Mo CHIEF SCIENTIFIC OFFICER Feb 16 '24 Sale 15.74 2,512 39,547 147,019 Feb 20 04:58 PM Parlavecchio Caryn CHRO Feb 16 '24 Sale 15.74 3,751 59,053 157,744 Feb 20 04:52 PM Ho Junlin GENERAL COUNSEL Feb 16 '24 Sale 15.74 3,489 54,928 208,771 Feb 20 04:48 PM Backstrom Jay T. CHIEF EXECUTIVE OFFICER Feb 16 '24 Sale 15.74 11,614 182,842 352,671 Feb 20 04:46 PM Qatanani Mo SVP AND HEAD OF RESEARCH Jan 16 '24 Sale 15.93 2,002 31,889 78,816 Jan 18 04:11 PM Parlavecchio Caryn CHRO Jan 16 '24 Sale 15.93 2,849 45,381 114,350 Jan 18 04:08 PM Myles Edward H COO & CFO Jan 16 '24 Sale 15.93 6,634 105,670 162,150 Jan 18 04:07 PM Ho Junlin GENERAL COUNSEL Jan 16 '24 Sale 15.93 4,186 66,677 154,405 Jan 18 04:05 PM Myles Edward H COO & CFO Dec 29 '23 Option Exercise 4.86 12,459 60,551 181,243 Dec 29 07:13 PM Myles Edward H COO & CFO Dec 29 '23 Sale 18.83 12,459 234,633 168,784 Dec 29 07:13 PM Qatanani Mo SVP AND HEAD OF RESEARCH Dec 14 '23 Option Exercise 10.00 8,437 84,370 105,480 Dec 15 04:13 PM Qatanani Mo SVP AND HEAD OF RESEARCH Dec 14 '23 Sale 18.18 24,662 448,444 80,818 Dec 15 04:13 PM Myles Edward H COO & CFO Dec 07 '23 Option Exercise 4.86 24,914 121,082 193,698 Dec 08 04:12 PM Myles Edward H COO & CFO Dec 07 '23 Sale 17.53 24,914 436,820 168,784 Dec 08 04:12 PM Myles Edward H COO & CFO Nov 02 '23 Sale 12.51 35,007 438,039 168,784 Nov 03 06:11 PM AKKARAJU SRINIVAS Director Oct 16 '23 Buy 6.85 2,189,781 15,000,000 6,788,609 Oct 18 05:46 PM Samsara BioCapital GP, LLC 10% Owner Oct 16 '23 Buy 6.85 2,189,781 15,000,000 6,788,609 Oct 18 05:44 PM Invus Public Equities, L.P. 10% Owner Oct 12 '23 Buy 6.86 2,199,931 15,086,736 11,259,438 Oct 16 05:46 PM Qatanani Mo SVP AND HEAD OF RESEARCH Sep 18 '23 Sale 6.34 1,945 12,331 97,043 Sep 20 07:28 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
